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Abstract 
Background:  To study  the association of serum 
ferritin levels with haematological parameters in 
thalassaemia  major patients.   
Methods: A total of 135 patients of thalassemia 
major were selected for this descriptive, cross 
sectional study.  Patients were divided into three 
groups. Group I consisted of patients with ferritin 
levels <2500 ng/ml. Group II comprised of patients 
having ferritin levels   2500 to 5000 ng/ml. Group III 
comprised of patients having ferritin > 5000 ng/ml. 
After taking patient history, complete blood count 
analysis and serum ferritin level determination was 
performed. 
Results: The mean ferritin level of  study group 
was 6062.61 + 3641.796 ng/ml. Most of our patients 
were receiving less than optimal level of chelation 
therapy. The number of red cells and platelets in 
patients with ferritin levels >5000ng/ml were found 
to be significantly lower ((p=0.0262, and 0.0265 
respectively), when compared with patients having 
ferritin levels <2,500 ng/ml. Other CBC parameters 
did not show any significant difference between the 
three ferritin groups.  
Conclusion: High ferritin levels are associated 
with less than optimal chelation therapy. Lower red 
cell and platelet counts were observed in patients 
with high ferritin levels. A complete blood count 
analysis is essential to avoid complications 
associated with low cell counts.      
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Introduction 
         Thalassemia is an autosomal recessive, inherited 
defect in the synthesis of haemoglobin. The patients 
suffer ineffective bone marrow erythropoesis and 
increased red cell haemolysis resulting in anaemia.1,2 
Clinically, the alpha and beta thalassemias merit 
importance.3 Beta thalassemia has a widespread 
occurrence in the Mediterranean region, Africa, the 
Middle East, India, Pakistan, Southeast Asia and the 
Indochina peninsula.4 In Pakistan, the prevalence of 
thalassemia is 5-8% and every year, 5000 children are 
born with this condition. Due to the high prevalence of 
this disease and poor health care facilities, it is 
considered a major health predicament in our 
country.5  
   It is usually diagnosed in the first year after birth, 
and thereafter, patients need regular blood 
transfusions for survival.6 The transfused blood helps 
to ameliorate the anaemia but after about a year of 
regular transfusion therapy, iron excess occurs in the 
body, ultimately resulting in deposition of iron in the 
heart, liver, endocrine glands and other organs, 
causing damage.7 Iron chelation therapy is undertaken 
in thalassemia major patients to remove the excess iron 
from the body in order to avoid lethal complications. 8 
  
Patients and Methods 
   This  cross sectional  study was conducted at 
Ziauddin University, Karachi from February 2013 to 
September, 2014. Patients were recruited from  
Fatimid Foundation, Karachi. Patients (n=135) 
included in the study were 7 years of age and above, 
and receiving at least 8 transfusion per year. Patients 
excluded from the study were those with any acute 
illness, known disease of the heart, liver, kidney or the 
thyroid gland, diabetes mellitus, any 
haemoglobinopathy other than thalassemia major, and 
those with a history of successful bone marrow 
transplantation. Patients were divided into three 
groups. Group I consisted of patients with ferritin 
levels <2500 ng/ml. Group II comprised of patients 
having ferritin levels   2500 to 5000 ng/ml. Group III 
comprised of patients having ferritin > 5000 ng/ml. 
Serum ferritin analysis was performed by 
Chemiluminescent Microparticle Immuno Assay 
(CMIA) technology using automatic immunoanalyzer. 
(normal range:18-323 ng/ml) . Complete Blood Count 
(CBC) was performed on automated hematology 
analyzer. 
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Results 
    A total of 135 patients were included in the study 
with ages ranging from 7-30 years. Males constituted 
51 %. About half of our patients (50.4%) were in the 7-
14 year age group. There were more females than 
males in the older (15-22 years and 23-30 years) age 
groups. All the major ethnic groups were seen in our 
study sample. The most frequently observed patients 
were Sindhi (35.6%), followed by the Balochis and 
Pathans. . Blood group analysis revealed Group B to 
be the most common amongst our sample (37%). A 
positive family history of thalassemia was recorded in 
73.3% of the patients, and 81.5% of them gave a history 
of consanguineous marriage of parents (Table 1).The 
mean ferritin  was 6062.61 + 3641.796 ng/ml and, the 
highest mean ferritin level was seen in the 23-30 year 
age group. Males had a mean ferritin level of 6340.90 
+3692.18 ng/ml while females had a mean ferritin of 
5771.67 + 3593.32 ng/ml. This difference in mean 
ferritin levels between genders was not found to be 
statistically significant (p=0.366). Injection 
Desferoxamine (500mg) was used as iron chelation 
therapy by all the patients. However, 75.6% of the 
patients were taking 10 or fewer injections per month, 
14.8% were receiving 11-20 injections /month and only 
9.6%were receiving more than 20 injections /month. 
Table1: Beta thalassaemia major-
Demographic profile 
Variables  No(%) 
Gender Male 69(51) 
Female 66(49) 
Age 7-14 years 68(50.4) 
15-22 years 57(42.2) 
23-30 years 10(7.4) 
Blood Groups A 31(23) 
B 50(37) 
AB 11(08) 
O 43(32) 
Ethnicity Balochis 31(23) 
Pathans 21(15.6) 
Punjabi 18(13.3) 
Sindhi 48(35.6) 
Urdu Speaking 12(8.8) 
Others 05(3.7) 
Family History of 
Thalassemia 
Yes 99(73.3) 
No 36(26.7) 
Consanguinity Yes 110(81.5) 
No 25(18.5) 
Laboratory findings regarding Complete Blood Count, 
(CBC), in the three ferritin groups showed that the 
number of RBC s and platelets in group III (Ferritin 
levels >5000 ng/ mL) were significantly lower than in 
group I (p=0.0262, and 0.0265 respectively). However, 
a significant correlation was not observed. Other CBC 
parameters like hemoglobin, hematocrit, WBC count  
Table 2: Beta thalassaemia-Gender frequency 
Ferritin levels Males Females 
No(%) No(%) 
  Group I(< 2500    ng/ml) 14(42) 19(58) 
Group II (2500- 5000 
ng/ml) 
26(54) 22(46) 
Group III (>5000ng/ml) 29(54) 25(46) 
Table3: Complete blood count findings 
according to ferritin levels 
  
Group I  
(Ferritin <2500 
ng/ml) 
Group II 
(Ferritin 2500-
5000ng/ml) 
Group III 
(Ferritin >5000 
ng/ml) P1 P2 
  N (33) N (48) N (54)     
Hb(gm/dL) 8.1 + 1.1 7.9 + 1.3 7.8 + 1.4 p=0.4717 p=0.2975 
WBCs(x103/µL) 6.7 + 2.8 6.4 + 2.5 6.1 + 3.3 p=0.6148 p=0.3867 
RBCs(x10 6/µL) 3.1 + 0.4 2.9 + 0.5 2.9 + 0.4 p=0.0593 p=0.0262* 
Platelets 
(x10 3/µL) 255.1 + 129.9 213.8 + 102.3 197.5 + 105.8 p=0.114 p=0.0265* 
MCV(fL) 78.3 + 5.5 79.3 + 4.7 79.7 + 4.2 p=0.3829 p=0.1841 
MCH(pg) 26.3 + 2.1 26.9 + 2.1 26.8 + 1.6 p=0.2101 p=0.2133 
MCHC(g/dL) 36.9 + 19.4 33.9 + 1.3 33.5 + 0.8 p=0.2875 p=0.2002 
Neutrophils(%) 47.4 + 10.3 48.4 + 11.2 47.1 + 9.7 p=0.6845 p=0.8916 
*=Statistical Significance;P1=comparison of group II with group I ,   
P2=comparison of group III with group I 
and neutrophils were lower in group III as compared 
to group I, but the difference was not statistically 
significant. Moreover, red cell indices (MCV, MCH 
and MCHC) also did not show any statistically 
significant difference between the three ferritin 
groups. (Table 3) 
 
Discussion 
    Transfusion dependant patients receive, on an 
average, 20 times the normal intake of iron, thus, iron 
overload is inevitable. For assessment of iron load of 
the body, serum ferritin is the most commonly 
employed test, as it is simple, cost effective and readily 
available.9,10 A better prognosis for survival in 
thalassemia major patients, receiving regular blood 
transfusions, is seen in whom serum ferritin levels 
remain below 2,500 ng/ml.11 In present study the 
mean serum ferritin was higher than that recorded in 
other studies.7,12,13  This could be the possible reason 
for the increased frequency of disease complications 
and low life expectancy in our thalassaemic 
population.The recommended dose of Desferoxamine 
is 30-40mg/kg /day, and most of our patients are 
receiving much below this dose. The high cost of 
chelation therapy and poor availability of infusion 
pumps may be the reason behind this low use.14.  
   Survival probability in thalassaemia major shows a 
rapid and marked decline from the second decade of 
life onwards. 10 In present study, majority of  patients 
were from the youngest age group and fewer were in 
the older age groups. This is indicative of poor life 
expectancy in thalassemia major patients leading to 
early death. Similar results have been observed in 
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studies conducted elsewhere previously.13,15Female 
gender in thalassemia major is associated with a better 
survival rate and a lower frequency of heart failure 
and arrthymias.10 Better compliance and adherence to 
chelation therapy on the part of female patients has 
been suggested as a possible explanation of this 
observation.10,13,15-17 
    In Pakistan, beta thalassemia is found in all 
population groups 5,18. In our study, we observed the 
same, in that, all the major ethnic groups made up our 
sample. The high frequency in certain ethnic groups 
may be explained on the basis of cultural preference 
for consanguineous marriages in those groups.18 
    Beta Thalassemia is characterized by ineffective 
erythropoesis, increased haemolysis and proliferation 
of extra - medullary haematopoetic sites which may 
lead to hepatosplenomegaly and subsequent 
hypersplenism .This over activity of the spleen further 
worsens the anaemic state of the patient with an 
increase in blood transfusion need and consequently 
increased ferritin levels 19. In our study, CBC of 
patients revealed that the number of RBCs and 
platelets in the highest ferritin group were 
significantly less, when compared with the lowest 
ferritin group. A higher number of blood transfusions, 
along with a greater extent of iron overload, with a 
probably greater level of hypersplenism, may be the 
likely reason for the significantly lower red cell and 
platelet counts observed in Group III. A previous 
study on thalassemia major patients showed that on 
performance of splenectomy, platelet count in the 
patients increased, thus, supporting our explanation 20. 
Moreover, an earlier study demonstrated that a low 
platelet count was observed in patients with high 
levels of ferritin and as the ferritin levels decreased 
significantly by the use of Deferiprone therapy, the 
platelet levels increased 21. In non-splenectomised 
patients, the mean blood requirement is 35% higher 
than in patients who have undergone splenectomy.22  
 
Conclusion 
1. Lower red cell and platelet counts were observed 
in patients with high ferritin levels. 
2.  In order to keep ferritin levels low, efforts need to 
be made to ensure proper chelation therapy. 
3.  Monitoring of serum ferritin levels, to prevent 
iron overload with all its inherent complications, 
and a complete blood count analysis is essential to 
avoid complications associated with low cell 
counts.       
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